View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 8, 2022

Tevogen begins final dose level in study of Covid-19 cell therapy

The trial will assess the safety and optimal dose of its cell therapy in high-risk Covid-19 patients.

Tevogen Bio has commenced the fourth and final dose level in an open-label clinical trial of its investigational T cell therapy, TVGN-489, to treat Covid-19 patients who are at increased risk.

A purified, genetically unmodified SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte (CTL) product, TVGN-489 could identify targets spread across the complete viral genome.

The trial will assess the safety and optimal dose of its cell therapy in high-risk Covid-19 patients aged 18 years and above with predefined high-risk criteria or those aged 65 years or above with or without priorly detected comorbid conditions.

Subjects treated with the investigational product will be compared to those who receive standard of care within the context of the trial.

Subjects in the third cohort were given a single 1 x 106cells/kg dose of TVGN-489, a dosing level greater than the first and second cohorts.

So far, no dose-limiting toxicities or treatment-associated adverse events, including cytokine release syndrome (CRS), were reported in any of the arms. 

In addition, all subjects in the three cohorts had a correction of lymphopenia, which is a speedy return to baseline in lymphocyte levels, analysed as a secondary outcome measure.

The subject enrolment in the study is anticipated to conclude in the second quarter of this year.

Tevogen CEO Ryan Saadi said: “Our next-generation T cell technology maintains the promise of developing target-specific cell therapies in oncology, virology, and neurology for large patient populations without requiring specialized medical facilities. 

“Additionally, I’m pleased to share that the company plans to study TVGN-489 for the prevention of Long Covid.”

In November last year, the company completed dosing of the first cohort of participants in the proof-of-concept trial of TVGN-489 to treat Covid-19 in the high-risk population.

Cell & Gene Therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena